Drugs / LABRADIMIL
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00001502 | Apr 1996 → Mar 2000 | glioma, medulloblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00002316 | — | Cryptococcal meningitis, HIV infectious disease | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00019422 | Mar 1998 → Apr 2003 | central nervous system neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LABRADIMIL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105864 ↗ |
| Known as | lobradimil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00019422 ↗ |
| Known as | RMP-7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001502 ↗ |
| Action | Activate | “Bradykinin B2 receptor agonist” CHEMBL2105864 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2105864 ↗ |
| Route | Intravenous | “Patients receive carboplatin IV over 15 minutes and lobradimil IV over 10 minutes on days 1 and 2.” NCT00019422 ↗ |
| Target | BDKRB2 | “Bradykinin B2 receptor agonist” CHEMBL2105864 ↗ |